Amgen shares took a hit Jan. 30, as the company reported declines in sales and its bottom line and delivered a muted outlook for 2020. The Thousand Oaks-based biotech giant cited encroachment from biosimilars and generics as the reason behind a 1 percent dip in sales for the fourth quarter to $6.2 billion. Overall in…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
